Angelini Pharma is the pharmaceutical division of Angelini Industries. The Group started almost 100 years ago as a small pharmaceutical laboratory, and over the years has grown into a leading international group in healthcare, present in Pharmaceuticals and Mass-Market.
Angelini Pharma is a leader in healthcare, with particular strength and expertise in the fields of Mental Health, Epilepsy and Rare Diseases. The company is also a leading player in the Consumer Health segment, with highly successful OTC brands worldwide.
Angelini Pharma products are marketed in about 70 countries. The company operates directly in 20 countries employing almost 3.000 people, and commercializes its products in more than 70 countries through strategic alliances with leading international pharmaceutical groups.
As part of its internationalisation strategy, Angelini Pharma has also concentrated on development in countries with high growth potential.
Angelini Pharma reported a turnover of more than €1 billion in 2021, about half accounted for by exports.
Angelini Pharma is an integrated pharmaceutical company, with an extensive R&D operation that has developed important molecules such as trazodone and benzydamine.
Current research focuses on Nervous System Diseases and Disorders, Pain and Inflammation and Rare Diseases, with a particular commitment to the research of new treatments for the paediatric population.
The research embraces public-private partnerships with recognised academic institutions and centres of global importance. The Scientific Network and Partnerships both have an important role in creating innovation.
Angelini Pharma's “world class” production plants use cutting-edge technologies and have full certification for quality standards and respect for the environment.
In Italy, finished pharmaceutical products are produced in the Ancona plant, while the industrial factory in Aprilia produces pharmaceutical raw materials. Disinfectants and sanitising products under the Amuchina brand are produced in Casella. These sites make extensive use of renewable energy sources and meet criteria of sustainability. Finally, the Albany (Georgia, USA) plant produces self-heating wraps under the ThermaCare® brand and the Barcelona plant (Spagna) produces food supplements such as Pastillas Juanola.
Angelini Pharma is responsible for the development and commercialization of cenobamate, an investigational anti-seizure medicine.
Angelini Pharma is Marketing Authorisation Holder of Ontozry®1 in Switzerland. For full information about the product please visit www.swissmedicinfo.ch.
1 Ontozry® is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products. Active ingredient: Cenobamate.